Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.

Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, MarÍn S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O; AB10015 STUDY GROUP.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 Jul 7:1-10. doi: 10.1080/21678421.2019.1632346. [Epub ahead of print]

PMID:
31280619
2.

Edaravone administration in pivotal clinical Study 19.

Genge A, Brooks B.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):298-299. doi: 10.1080/21678421.2019.1582672. Epub 2019 May 13. No abstract available.

PMID:
31079469
3.

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group.

Neurology. 2019 Apr 2;92(14):e1610-e1623. doi: 10.1212/WNL.0000000000007242. Epub 2019 Mar 8.

4.

Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.

Hodgkinson VL, Lounsberry J, Mirian A, Genge A, Benstead T, Briemberg H, Grant I, Hader W, Johnston WS, Kalra S, Linassi G, Massie R, Melanson M, O'Connell C, Schellenberg K, Shoesmith C, Taylor S, Worley S, Zinman L, Korngut L.

Can J Neurol Sci. 2018 Nov;45(6):652-659. doi: 10.1017/cjn.2018.311.

PMID:
30430962
5.

Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R.

Jackson C, De Carvalho M, Genge A, Heiman-Patterson T, Shefner JM, Wei J, Wolff AA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):506-512. doi: 10.1080/21678421.2018.1497658. Epub 2018 Oct 31.

PMID:
30379086
6.

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.

Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP; FORCIDP Trial Investigators.

Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9. Erratum in: Lancet Neurol. 2018 Nov;17(11):933.

7.

A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD).

Waito AA, Steele CM, Peladeau-Pigeon M, Genge A, Argov Z.

Dysphagia. 2018 Dec;33(6):789-802. doi: 10.1007/s00455-018-9904-9. Epub 2018 May 3.

PMID:
29725764
8.

Understanding the use of NIV in ALS: results of an international ALS specialist survey.

Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):331-341. doi: 10.1080/21678421.2018.1457058. Epub 2018 Apr 16.

PMID:
29661084
9.

Respiratory measures in amyotrophic lateral sclerosis.

Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):321-330. doi: 10.1080/21678421.2018.1452945. Epub 2018 Mar 23. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):478.

PMID:
29566571
10.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group.

Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28.

11.

Hair product artifact in magnetic resonance imaging.

Chenji S, Wilman AH, Mah D, Seres P, Genge A, Kalra S.

Magn Reson Imaging. 2017 Jan;35:1-3. doi: 10.1016/j.mri.2016.08.023. Epub 2016 Aug 30.

PMID:
27590880
12.

Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel.

Tarnopolsky M, Katzberg H, Petrof BJ, Sirrs S, Sarnat HB, Myers K, Dupré N, Dodig D, Genge A, Venance SL, Korngut L, Raiman J, Khan A.

Can J Neurol Sci. 2016 Jul;43(4):472-85. doi: 10.1017/cjn.2016.37. Epub 2016 Apr 8. Review.

PMID:
27055517
13.

Reevaluating Muscle Biopsies in the Diagnosis of Pompe Disease: A Corroborative Report.

Genge A, Campbell N.

Can J Neurol Sci. 2016 Jul;43(4):561-6. doi: 10.1017/cjn.2016.29. Epub 2016 Apr 4.

PMID:
27039993
14.

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome.

Kaminska M, Browman F, Trojan DA, Genge A, Benedetti A, Petrof BJ.

PM R. 2015 Jul;7(7):677-684. doi: 10.1016/j.pmrj.2015.04.001. Epub 2015 Apr 3.

PMID:
25845857
15.

A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.

Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, Simpson E, Genge A, Bertorini T, Fernandes JA, Swenson A, Elman L, Dimachkie M, Herbelin L, Miller J, Lu J, Wilkins H, Swerdlow RH, Statland J, Barohn R; Western ALS (WALS) Rasagiline Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):345-52. doi: 10.3109/21678421.2015.1026826. Epub 2015 Apr 2.

16.

The Search for Pompe Patients in Canada: Assessing Feasibility of a National Disease Registry to Facilitate Research.

Korngut L, Johnston M, Campbell C, Genge A, MacKenzie A, McCormick A, Venance S.

J Neuromuscul Dis. 2015;2(s1):S45-S46. No abstract available.

PMID:
27858639
17.

Screening for Pompe Disease in Specific At-Risk Populations with Sleep-Disordered Breathing.

Kaminska M, Noel F, Genge A, Melancon SB, Pshezhetsky A, Petrof BJ.

J Neuromuscul Dis. 2015;2(s1):S44. No abstract available.

PMID:
27858638
18.

Validation and interpretation of neurological registry data.

Pringsheim T, Lam D, Day L, Genge A, Hogan DB, Shevell M, Fortin CM, Maxwell C, Fiebelkorn G, Barlow K, Kapral MK, Casha S, Mobach T, Johnston M, Jette N, Korngut L.

Can J Neurol Sci. 2013 Jul;40(4 Suppl 2):S51-3. Review. No abstract available.

PMID:
23787269
19.

Patient recruitment by neurological registries.

Hamilton M, Genge A, Johnston M, Lam D, Mobach T, Marriott J, Steeves T, Donner E, Wysocki J, Barlow K, Shevell M, Marrie RA, Casha S, Mackean G, Casselman L, Korngut L, Pringsheim T, Jette N.

Can J Neurol Sci. 2013 Jul;40(4 Suppl 2):S23-6. Review. No abstract available.

PMID:
23787262
20.

The CNDR: collaborating to translate new therapies for Canadians.

Korngut L, Campbell C, Johnston M, Benstead T, Genge A, Mackenzie A, McCormick A, Biggar D, Bourque P, Briemberg H, O'Connell C, Dojeiji S, Dooley J, Grant I, Hogan G, Johnston W, Kalra S, Katzberg HD, Mah JK, McAdam L, McMillan HJ, Melanson M, Selby K, Shoesmith C, Smith G, Venance SL, Wee J; CNDR Investigator Network.

Can J Neurol Sci. 2013 Sep;40(5):698-704.

PMID:
23968944
21.

Establishing a Canadian registry of patients with amyotrophic lateral sclerosis.

Korngut L, Genge A, Johnston M, Benstead T, Bourque P, Briemberg H, Casey A, D'Amour M, Dupré N, Figlewicz D, Hader W, Johnston W, Kalra S, Melanson M, O'Connell C, Rouleau G, Shoesmith C, Wee J, Zinman L.

Can J Neurol Sci. 2013 Jan;40(1):29-35.

PMID:
23250124
22.

Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.

Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, Mozaffar T.

J Neuropathol Exp Neurol. 2011 Jan;70(1):96-7; author reply 98-100. doi: 10.1097/NEN.0b013e318204782b. No abstract available.

PMID:
21173608
23.

Incidence and prevalence of amyotrophic lateral sclerosis in Canada: a systematic review of the literature.

Wolfson C, Kilborn S, Oskoui M, Genge A.

Neuroepidemiology. 2009;33(2):79-88. doi: 10.1159/000222089. Epub 2009 May 30. Review.

24.

[Assessment of retrocochlear hearing pathway activity in infants with central nervous system impairment occurring as an effect of perinatal asphyxia].

Widziszowska A, Namysłowski G, Genge A, Hajduk A, Godula-Stuglik U.

Otolaryngol Pol. 2008;62(4):471-5. doi: 10.1016/S0030-6657(08)70295-6. Polish.

PMID:
18837227
25.

Mechanisms responsible for the enhanced pumping capacity of the in situ winter flounder heart (Pseudopleuronectes americanus).

Mendonça PC, Genge AG, Deitch EJ, Gamperl AK.

Am J Physiol Regul Integr Comp Physiol. 2007 Nov;293(5):R2112-9. Epub 2007 Aug 29.

26.

Codman Award 2006: the experience of hope in ALS patients.

Vitale A, Genge A.

Axone. 2007 Winter;28(2):27-35.

PMID:
17460956
27.

Cerebral degeneration predicts survival in amyotrophic lateral sclerosis.

Kalra S, Vitale A, Cashman NR, Genge A, Arnold DL.

J Neurol Neurosurg Psychiatry. 2006 Nov;77(11):1253-5. Epub 2006 Jul 11.

28.
29.

[Assessment of cochlea activity in a group of newborns with central nervous system impairment as an effect of perinatal asphyxia using click-evoked otoacoustic emissions (CEOAEs)].

Widziszowska A, Namysłowski G, Genge A, Buczyńska G, Hajduk A, Godula-Stuglik U.

Pol Merkur Lekarski. 2005 Sep;19(111):312-4. Polish.

PMID:
16358854
30.

Linking swimming performance, cardiac pumping ability and cardiac anatomy in rainbow trout.

Claireaux G, McKenzie DJ, Genge AG, Chatelier A, Aubin J, Farrell AP.

J Exp Biol. 2005 May;208(Pt 10):1775-84.

31.

Hydrates of tin tetrachloride.

Genge AR, Levason W, Patel R, Reid G, Webster M.

Acta Crystallogr C. 2004 Apr;60(Pt 4):i47-9. Epub 2004 Mar 31.

PMID:
15071197
32.
33.

Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy.

Kalra S, Cashman NR, Caramanos Z, Genge A, Arnold DL.

AJNR Am J Neuroradiol. 2003 Mar;24(3):476-80.

34.

Synthesis and Structure of NaZnSiO(3)OH, a New Chiral Zincosilicate Framework Material.

Healey AM, Weller MT, Genge AR.

Inorg Chem. 1999 Feb 8;38(3):455-458.

PMID:
11673948
35.

Muscle diseases.

Genge A, Shapira AH, Griggs RC.

J Clin Neuromuscul Dis. 1999 Dec;1(2):114. No abstract available.

PMID:
19078567
36.

Intracellular phosphates in inclusion body myositis--a 31P magnetic resonance spectroscopy study.

Argov Z, Taivassalo T, De Stefano N, Genge A, Karpati G, Arnold DL.

Muscle Nerve. 1998 Nov;21(11):1523-5.

PMID:
9771678
37.

Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy.

Kalra S, Cashman NR, Genge A, Arnold DL.

Neuroreport. 1998 Jun 1;9(8):1757-61.

PMID:
9665596
38.

Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis.

Horvath R, Fu K, Johns T, Genge A, Karpati G, Shoubridge EA.

J Neuropathol Exp Neurol. 1998 May;57(5):396-403.

PMID:
9596410
39.

Effects of aerobic training in patients with mitochondrial myopathies.

Taivassalo T, De Stefano N, Argov Z, Matthews PM, Chen J, Genge A, Karpati G, Arnold DL.

Neurology. 1998 Apr;50(4):1055-60.

PMID:
9566394
41.

Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency.

Taivassalo T, Matthews PM, De Stefano N, Sripathi N, Genge A, Karpati G, Arnold DL.

Neurology. 1996 Aug;47(2):529-34.

PMID:
8757032
42.

Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders.

De Stefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL.

Neurology. 1995 Jun;45(6):1193-8.

PMID:
7783888
43.

Familial myopathy with conspicuous depletion of mitochondria in muscle fibers: a morphologically distinct disease.

Genge A, Karpati G, Arnold D, Shoubridge EA, Carpenter S.

Neuromuscul Disord. 1995 Mar;5(2):139-44.

PMID:
7767093

Supplemental Content

Support Center